Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported a Form 4 transaction involving company common stock. On 02/08/2026, 36,687 shares of common stock were withheld by the issuer at $6.52 per share to cover tax withholding obligations tied to vesting restricted stock units.
After this tax withholding, Schuetz beneficially owns 6,603,336 shares of common stock. This includes unvested RSUs: 125,000 shares from a February 8, 2023 grant vesting in four equal annual installments starting February 8, 2024; 318,750 shares from a January 9, 2024 grant vesting annually starting January 9, 2025; and 250,000 shares from a January 2, 2026 grant vesting annually starting January 2, 2027.
Compass Therapeutics, Inc. (CMPX) reported that BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in the company’s common stock. BlackRock reports beneficial ownership of 9,271,644 shares of Compass Therapeutics common stock, representing 5.2% of the outstanding class as of the reported date.
BlackRock has sole voting power over 9,138,337 shares and sole dispositive power over 9,271,644 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and are not intended to change or influence control of Compass Therapeutics. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single one has more than five percent of the total outstanding shares.
Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported an automatic share withholding related to equity compensation. On January 9, 2026, 46,777 shares of common stock were withheld by the company at $5.35 per share to cover tax obligations arising from the vesting of restricted stock units. After this tax withholding, Schuetz beneficially owned 6,640,023 shares of common stock.
The filing also notes unvested restricted stock units: 250,000 RSUs from a February 8, 2023 grant, 318,750 RSUs from a January 9, 2024 grant, and 250,000 RSUs from a January 2, 2026 grant. Each award vests in four equal annual installments, with first vesting dates in 2024, 2025, and 2027, respectively.
Compass Therapeutics, Inc. (CMPX) reported an insider ownership update for Chief Executive Officer and Director Thomas J. Schuetz. On 11/16/2025, 44,025 shares of common stock were withheld at a price of $4.83 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this tax withholding transaction, Schuetz beneficially owns 6,436,800 shares of Compass Therapeutics common stock.
The filing notes that 250,000 of these shares relate to unvested RSUs granted on February 8, 2023, which vest in four equal annual installments starting on February 8, 2024. An additional 478,125 shares relate to unvested RSUs granted on January 9, 2024, also vesting in four equal annual installments beginning on January 9, 2025. Each RSU represents a contingent right to receive one share of common stock, subject to continued service-based vesting conditions.
Compass Therapeutics (CMPX) reported Q3 2025 results, highlighting a stronger balance sheet and continued R&D investment. Cash, cash equivalents and marketable securities were $220 million as of September 30, 2025, and management said this resources level is expected to fund operations into 2028.
Q3 operating expenses were $15.8 million, driven by research and development of $12.8 million (up 49% year over year) and general and administrative of $3.0 million (down 18%). Net loss for Q3 was $14.3 million, or $0.08 per share, and $50.8 million for the nine months.
The company completed an underwritten offering on August 12, 2025, issuing common stock and pre-funded warrants, for net proceeds of $129.3 million. As of October 30, 2025, shares outstanding were 177,862,102.
Pipeline updates included: analyses of overall survival and progression-free survival from the Phase 2/3 BTC study of tovecimig expected in late Q1 2026, and full topline Phase 1 data for CTX-8371 planned for the first half of 2026, with cohort expansions in NSCLC and TNBC planned this quarter.
Compass Therapeutics, Inc. filed a current report to share that it has released its financial results for the quarter and nine months ended September 30, 2025. The company reported these results via a press release dated November 5, 2025, which is attached to the report as an exhibit and incorporated by reference. The filing is focused on making this earnings information available to the market and does not itself detail the specific revenue, profit, or cash figures.
Compass Therapeutics, Inc. received an amendment to a Schedule 13G reporting that Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen together filed ownership information for the issuer's common stock (CUSIP 20454B104). Suvretta reports beneficial ownership of 14,101,159 shares (8.2% of the class) with shared voting and dispositive power. Averill Master Fund reports 12,229,050 shares (7.1%) with shared voting and dispositive power. Aaron Cowen is reported with the same 14,101,159 shares (8.2%). The filing states these securities are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to their pecuniary interest.
Amendment No. 1 to the Schedule 13D reports that a group of related reporting persons collectively beneficially own 7,788,150 shares of Compass Therapeutics common stock, representing 4.5% of the outstanding shares based on 171,572,498 shares outstanding as of the issuer's prospectus. The amendment states the ownership percentage declined due to a decrease in the issuer's outstanding shares, and as a result the reporting entities "ceased to exceed 5%" and are no longer subject to Section 13 reporting. The filing also confirms no transactions in the common stock by the reporting entities in the past 60 days and identifies the reporting persons and their shared voting and dispositive power over the disclosed shares.
OrbiMed Advisors LLC and OrbiMed Capital GP V LLC filed Amendment No. 6 to their Schedule 13D for Compass Therapeutics, Inc. to report that their beneficial ownership decreased to 15,219,994 shares, representing approximately 8.9% of the outstanding common stock. The decrease in percentage ownership is attributed to an increase in the number of shares outstanding as disclosed in the issuer's prospectus. OrbiMed GP is the general partner of the limited partner that holds the shares and OrbiMed Advisors is the managing member of OrbiMed GP, giving the reporting persons shared power to vote and dispose of the shares. Carl L. Gordon, a member of OrbiMed Advisors, serves on the issuer's board.
Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital affiliates and Kevin Tang report shared beneficial ownership of 13,496,208 shares of Compass Therapeutics common stock, representing 9.8% of the outstanding class based on 138,282,498 shares outstanding as of April 28, 2025. The filing states no sole voting or dispositive power; all 13,496,208 shares are held with shared voting and shared dispositive power among Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; and Kevin Tang. The filing certifies the holdings were not acquired to change or influence control of the issuer.